Brought to you by 
Vertex acquires Aurora for $570mm
21 Feb 2002
Executive Summary
In a tax-free stock swap worth $570mm, Vertex Pharmaceuticals will acquire fluorescence assay and screening platform company Aurora Biosciences. Based on the companies’ trading prices before announcement, Vertex will pay a (pr)56% premium for the shares, at $24.34 apiece. Each Aurora share converts to 0.62 shares of Vertex common; Vertex will issue about 14mm new shares.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- ADMET
- Genomics-Proteomics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com